Female Hormone Powders Mifepristone CAS 84371-65-3 for Body Healthcare

Female Hormone Powders Mifepristone CAS 84371-65-3 for Body Healthcare

Mifepristone

Synonyms: 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-9-dien-3-one;11beta-[4-(n,n-dimethylamino)phenyl]-17alpha-(prop-1-ynyl)-delta4,9-estradiene;17-beta)-(11-bet;17beta)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-(11bet;17-beta-hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oest;-17beta-ol-3-one;4,9-dien-3-one;r38486 
CAS: 84371-65-3 
MF: C29H35NO2 
MW: 429.59 

Chemical Properties Pale Yellow Solid 
Usage A progesterone receptor antagonist with partial agonist activity. Abortifacient.  
Usage glutamate uptake inhibitor, AMPA blocker 
Biological Activity Selective antagonist at progesterone (PR) and glucocorticoid (GR) receptors in vitro and in vivo . Is a silent antagonist at PR and has a higher affinity than progesterone. Has higher affinity for GR than dexamethasone.

Mifepristone  Description:
 
Mifepristone (or RU-486) is a synthetic steroid compound with both antiprogesterone and antiglucocorticoid properties. The compound is a 19-nor steroid with substitutions at positions C11 and C17 (17 beta-hydroxy-11 beta-[4-dimethylamino phenyl] 17 alpha-[1-propynyl]estra-4,9-dien-3-one), which antagonizes cortisol action competitively at the receptor level.
 
Mifepristone is a progesterone receptor antagonist used as an abortifacient in the first months of pregnancy, and in smaller doses as an emergency contraceptive. It is also a powerful glucocorticoid receptor antagonist, and has occasionally been used in refractory Cushings syndrome (due to ectopic/neoplastic ACTH/cortisol secretion). During early trials, it was known as RU-38486 or simply RU-486, its designation at the Roussel Uclaf company, which designed the drug. The drug was initially made available in France, and other countries then followed—often amid controversy. It is marketed under tradenames Korlym and Mifeprex, according to FDA Orange Book.
 
Mifepristone was the first antiprogestin to be developed and it has been evaluated extensively for its use as an abortifacient. The original target for the research group, however, was the discovery and development of compounds with antiglucocorticoid properties. These antiglucocorticoid properties are of great interest in the treatment of severe mood disorders and psychosis, although a review of published articles was inconclusive on their efficacy, and considered the use of these drugs in mood disorders at proof of concept stage. It is on the World Health Organizations List of Essential Medicines.

 
Mifepristone is used alone or in combination with misoprostol (Cytotec) to end an early pregnancy. Early pregnancy means it has been 49 days or less since your last menstrual period began. Mifepristone is in a class of medications called antiprogestational steroids. It works by blocking the activity of progesterone, a substance your body makes to help continue pregnancy.
 
Mifepristone is also available as another product (Korlym), which is used to control hyperglycemia (high blood sugar) in people with a certain type of Cushings Syndrome in which the body makes too much of the hormone cortisol. This monograph only gives information about mifepristone (Mifeprex), which is used alone or in combination with another medication to end an early pregnancy. If you are using mifepristone to control hyperglycemia caused by Cushings syndrome, read the monograph entitled mifepristone (Korlym) that has been written about this product.
 
Mifepristone  Specifications:
 

Recommend Steroids Hormone Powder:

Female Hormone Powders Mifepristone CAS 84371-65-3 for Body Healthcare Images